Australia's most trusted
source of pharma news
Posted 9 July 2025 AM
Astellas Pharma’s first-in-class CLDN18.2 drug Vyloy has overcome a major funding hurdle, with MSAC supporting a test that could see the blockbuster-in-waiting added to the PBS, if the company takes a price cut.
Vyloy in combination with fluropyrimidine-and platinum-containing chemotherapy, is intended for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (G/GOJ) cancer whose tumours are CLDN18.2 positive.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.